Merck Recalls One Lot Of Cubicin Antibiotic Over Glass Particles Presence In Vials

Merck Recalls One Lot Of Cubicin Antibiotic Over Glass Particles Presence In Vials
  • Merck & Co Inc MRK is voluntarily recalling one lot of Cubicin (daptomycin for injection) 500 mg with expiry June 2022. 
  • Approximately 22,000 vials will be affected by this recall. 
  • The recall was initiated after a customer complaint reported that a glass piece was found in a vial of Cubicin after reconstitution.
  • If used by the patient, local irritation or swelling at the infusion site may occur. More serious potential outcomes include blockage and clotting in blood vessels, life-threatening if a critical organ is affected. 
  • Other clinical consequences could include prolonged hospitalization.
  • Cubicin is a lipopeptide antibacterial indicated for complicated skin and skin structure infections (cSSSI) in adult and pediatric patients. 
  • Price Action: MRK shares are up 0.40% at $79.81 during the premarket session on the last check Wednesday. 

Posted In: BriefsrecallBiotechNewsHealth CareGeneral